Participated as an existing investor in Sling Therapeutics' Forbion-led Series C.
SEP 2026
Sling Therapeutics, Inc
Sling Therapeutics, Inc., is a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The company is advancing the evaluation of its lead product candidate, linsitinib, in a Phase 2b clinical trial based on extensive preclinical and clinical data.